Experimental combo for tough blood cancers shows early promise but trial halted
NCT ID NCT04937166
First seen Nov 11, 2025 · Last updated Jun 16, 2026 · Updated 32 times
Summary
This early-phase study tested a new drug called DSP107 combined with standard treatments for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) that had come back or not responded to prior therapy. The goal was to find safe doses and check for signs of effectiveness. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
The University of Texas MD Anderson Cancer Center, Department of Leukemia
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.